This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL et al., for the ICSG on MMM. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Hematol 1999; 104: 730–737.
Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia : a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
Cervantes F, Barosi G . Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors and staging. Semin Oncol 2005; 32: 395–402.
Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Hematol 1988; 70: 397–401.
Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stosk W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.
Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia: on behalf of the IWG for myelofibrosis research and treatment. Blood 2006; 108: 1497–1503.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourclas N, Swanton S et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorder. N Engl J Med 2005; 352: 1779–1790.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in intermediate or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fiorini, A., Reddiconto, G., Farina, G. et al. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. Leukemia 20, 2198–2199 (2006). https://doi.org/10.1038/sj.leu.2404430
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404430
This article is cited by
-
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
Bone Marrow Transplantation (2008)